Date: Jun 30, 2014 Source: NASDAQ News (
click here to go to the source)
Avalanche Biotechnologies, an early-stage biotech developing gene therapies for wet AMD and other ophthalmic diseases, filed on Monday with the SEC to raise up to $86 million in an initial public offering. The Menlo Park, CA-based company, which was founded in 2006, plans to list on the NASDAQ under the symbol AAVL. Avalanche Biotechnologies initially filed confidentially on May 30, 2014. Jefferies, Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
I'm Steve Reitmeister with Zacks Investment Research. We're releasing a free AAPL analysis that forecasts where it's heading in 1-3 months.
This prediction model is worth noting because it nearly triples the market's average yearly gain.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.